SRZN — Surrozen, Inc.
$25.48-1.05%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SRZN in the TickerWise workspace.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 40
- Website: https://www.surrozen.com
Latest SEC filings for SRZN
Latest SRZN news
- Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million Read article
- Surrozen advances diabetic macular edema candidate into clinic after IND clearance Read article
- Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.